Drug Type Chemical drugs, Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms HRS-1738 |
Target |
Action modulators |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| PSMA-Positive Prostatic Cancer | Phase 2 | China | 30 Jul 2025 | |
| Adenocarcinoma of prostate | Phase 2 | China | 01 Jul 2025 |





